Anas younes lymphoma survival rate

  • Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a.
  • As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients are increasingly being treated with multiple regimens.
  • The median OS and PFS after first-line treatment were 9.7 and 4.0 years, respectively.

    • •

    Abstract

    Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal outcome. Current clinical parameters do not allow accurate risk stratification, and personalized therapies are lacking. In fact, Hodgkin lymphoma (HL) is often over- or undertreated because of this lack of accurate risk stratification. In recent years, the early detection of chemoresistance by fluorodeoxyglucose positron emission tomography has become the most important prognostic tool in the management of HL. However, to date, no prognostic scores or molecular markers are available for the early identification of patients at very high risk of failure of induction therapy. In the last decade, many important advances have been made in understanding the biology of HL. In particular, the development of new molecular profiling technologies, such as SNP arrays, comparative genomic hybridization, and gene-expression p

    •

    Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

    As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients are increasingly being treated with multiple regimens. However, outcome after each line remains poorly characterized in the modern era. To address this knowledge gap, we retrospectively studied 404 consecutive MCL patients who were managed between 2000 and 2014 at Memorial Sloan Kettering Cancer Center. Histologic diagnosis was centrally confirmed, and patients were followed longitudinally from diagnosis throughout their disease course. Progression-free survival (PFS) and overall survival (OS) were determined by Kaplan-Meier method. The median OS and PFS after first-line treatment were 9.7 and 4.0 years, respectively. After second-line therapy, the mittvärdet i en uppsättning data OS and PFS were 41.1 and 14.0 months, third line were 25.2 and 6.5 months,

  • anas younes lymphoma survival rate

    • •

      In my role, I lead Haematology Oncology R&D, with responsibilities spanning from early discoveries and target identification, to first-in-human clinical studies, to late stage trials and drug approvals.

      I am a clinician-scientist and have spent more than 25 years caring for patients with lymphoma. Prior to joining AstraZeneca, I was at Memorial Sloan Kettering Cancer Center (MSKCC) where I served as the Chief of the Lymphoma Service, in addition to leading a laboratory focused on drug development for patients with lymphoid malignancies. Our lab was focused on accelerating the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Prior to MSKCC, I worked for 20 years at University of Texas MD Anderson Cancer Center (MDACC) where I directed clinical and translational research in the Department of Lymphoma and Myeloma.

       

      During m